Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedVersion history shows a new Revision: v3.4.2 added, and the funding-status notice along with Revision: v3.4.1 removed. These changes are limited to system-wide versioning and notices and do not modify study data or record content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a site-wide notice about potential data delays due to government funding issues and updated the page version to v3.4.1. Removed the previous v3.4.0.SummaryDifference0.6%

- Check28 days agoChange DetectedGlossary toggle is now shown and the history uses green highlights for additions and red for deletions, along with a visible Revision: v3.4.0 label. A No FEAR Act Data item was added to the page.SummaryDifference1%

- Check42 days agoChange DetectedThe history shows an added revision (v3.3.4) and a removal of revision v3.3.3, which is a minor update to the History page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedDifference0.3%

- Check64 days agoChange DetectedA new revision entry (Revision: v3.3.3) was added to the history, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.